Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The closing price of Phathom Pharmaceuticals Inc (NASDAQ: PHAT) was $15.6 for the day, down -13.72% from the previous closing price of $18.08. In other words, the price has decreased by -$13.72 from its previous closing price. On the day, 6.73 million shares were traded. PHAT stock price reached its highest trading level at $16.06 during the session, while it also had its lowest trading level at $15.15.
Ratios:
Our analysis of PHAT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.19 and its Current Ratio is at 2.23.
Upgrades & Downgrades
In the most recent recommendation for this company, Raymond James on December 12, 2025, initiated with a Strong Buy rating and assigned the stock a target price of $28.
On December 09, 2025, Barclays started tracking the stock assigning a Equal Weight rating and target price of $16.
On February 14, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $23.Cantor Fitzgerald initiated its Overweight rating on February 14, 2025, with a $23 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 03 ’25 when Breedlove Robert Charles sold 524 shares for $13.51 per share. The transaction valued at 7,079 led to the insider holds 47,407 shares of the business.
Breedlove Robert Charles sold 461 shares of PHAT for $5,573 on Sep 05 ’25. The Principal Accounting Officer now owns 47,931 shares after completing the transaction at $12.09 per share. On Jul 16 ’25, another insider, Breedlove Robert Charles, who serves as the Principal Accounting Officer of the company, sold 1,692 shares for $8.36 each. As a result, the insider received 14,152 and left with 48,392 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PHAT now has a Market Capitalization of 1109759744 and an Enterprise Value of 1557738368. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.54. Its current Enterprise Value per Revenue stands at 10.583 whereas that against EBITDA is -7.321.
Stock Price History:
The Beta on a monthly basis for PHAT is 0.52, which has changed by 1.6051874 over the last 52 weeks, in comparison to a change of 0.1877265 over the same period for the S&P500. Over the past 52 weeks, PHAT has reached a high of $18.31, while it has fallen to a 52-week low of $2.21. The 50-Day Moving Average of the stock is 3.29%, while the 200-Day Moving Average is calculated to be 53.58%.
Shares Statistics:
PHAT traded an average of 967.18K shares per day over the past three months and 620060 shares per day over the past ten days. A total of 71.04M shares are outstanding, with a floating share count of 41.31M. Insiders hold about 41.93% of the company’s shares, while institutions hold 50.71% stake in the company. Shares short for PHAT as of 1765756800 were 12677843 with a Short Ratio of 13.11, compared to 1763078400 on 13078808. Therefore, it implies a Short% of Shares Outstanding of 12677843 and a Short% of Float of 29.37.
Earnings Estimates
Investors are keenly observing as 5.0 analysts analyze and rate . The current performance of Phathom Pharmaceuticals Inc (PHAT) in the stock market.The consensus estimate for the next quarter is -$0.28, with high estimates of -$0.12 and low estimates of -$0.57.
Analysts are recommending an EPS of between -$2.07 and -$3.16 for the fiscal current year, implying an average EPS of -$2.33. EPS for the following year is -$0.13, with 5.0 analysts recommending between $0.4 and -$1.16.
Revenue Estimates
It is expected that $90B in revenue will be generated in . The current quarter, according to 4 analysts. It ranges from a high estimate of $57.5M to a low estimate of $57M. As of . The current estimate, Phathom Pharmaceuticals Inc’s year-ago sales were $29.66MFor the next quarter, 4 analysts are estimating revenue of $59.67M. There is a high estimate of $66.89M for the next quarter, whereas the lowest estimate is $55.6M.
A total of 4 analysts have provided revenue estimates for PHAT’s current fiscal year. The highest revenue estimate was $175M, while the lowest revenue estimate was $174M, resulting in an average revenue estimate of $174.63M. In the same quarter a year ago, actual revenue was $55.25MBased on 8 analysts’ estimates, the company’s revenue will be $316.41M in the next fiscal year. The high estimate is $334M and the low estimate is $290M.
